The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The evolution of body composition in oncology—epidemiology, clinical trials, and the future of patient care: facts and numbers
Open accessAbstract
There is growing interest from the oncology community to understand how body composition measures can be used to improve the delivery of clinical care for the 18.1 million individuals diagnosed with cancer annually. Methods that distinguish muscle from subcutaneous and visceral adipose tissue, such as computed tomography (CT), may offer new insights of important risk factors and improved prognostication of outcomes over alternative measures such as body mass index. In a meta‐analysis of 38 studies, low muscle area assessed from clinically acquired CT was observed in 27.7% of patients with cancer and associated with poorer overall survival [hazard ratio: 1.44, 95% CI: 1.32–1.56]. Therapeutic interventions such as lifestyle and pharmacotherapy that modify all aspects of body composition and reduce the incidence of poor clinical outcomes are needed in patients with cancer. In a meta‐analysis of six randomized trials, resistance training exercise increased lean body mass assessed from dual‐energy X‐ray absorptiometry [mean difference (MD): +1.07 kg, 95% CI: 0.76–1.37; P < 0.001] and walking distance [MD: +143 m, 95% CI: 70–216; P < 0.001] compared with usual care control in patients with non‐metastatic cancer. In a meta‐analysis of five randomized trials, anamorelin (a ghrelin agonist) significantly increased lean body mass [MD: +1.10 kg, 95% CI: 0.35–1.85; P = 0.004] but did not improve handgrip strength [MD: 0.52 kg, 95% CI: −0.09–1.13; P = 0.09] or overall survival compared with placebo [HR: 0.99, 95% CI: 0.85–1.14; P = 0.84] in patients with advanced or metastatic cancer. Early screening to identify individuals with occult muscle loss, combined with multimodal interventions that include lifestyle therapy with resistance exercise training and dietary supplementation combined with pharmacotherapy, may be necessary to provide a sufficient stimulus to prevent or slow the cascade of tissue wasting. Rapid, cost‐efficient, and feasible methods to quantify muscle and adipose tissue distribution are needed if body composition assessment is to be integrated into large‐scale clinical workflows. Fully automated analysis of body composition from clinically acquired imaging is one example. The study of body composition is one of the most provocative areas in oncology that offers tremendous promise to help patients with cancer live longer and healthier lives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr
Janssen, I., Heymsfield, S. B., Wang, Z., & Ross, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.89.1.81 · Cited by 3,087
Shen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M.-P., Albu, J., Heymsfield, S. B., & Heshka, S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00744.2004 · Cited by 1,692
Bluethmann, S. M., Mariotto, A. B., & Rowland, J. H. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0133 · Cited by 1,146 · cited 1×
“Underscoring the critical need for the evaluation of body composition in oncology, patients with cancer are often older adults who have experienced age-related alterations in body composition that may be further exacerbated by cancer and cancer treatments.(6,7) The field is eager to identify therapeutic interventions…”
BackgroundMuscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Cermak, N. M., Res, P. T., de Groot, L. C., Saris, W. H., & van Loon, L. J. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.037556 · Cited by 827
McQuade, J. L., Daniel, C. R., Hess, K. R., Mak, C., Wang, D. Y., Rai, R. R., Park, J. J., Haydu, L. E., Spencer, C., Wongchenko, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30078-0 · Cited by 664
Temel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Human Body Composition: Advances in Models and Methods
B. Heymsfield, S., Wang, Z., Baumgartner, R. N., & Ross, R. (1997) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.17.1.527 · Cited by 527
The reliability and validity of ultrasound to quantify muscles in older adults: A systematic review
Nijholt, W., Scafoglieri, A., Jager‐Wittenaar, H., Hobbelen, J. S. M., & van der Schans, C. P. (2017) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12210 · Cited by 459
Dobs, A. S., Boccia, R. V., Croot, C. C., Gabrail, N. Y., Dalton, J. T., Hancock, M. L., Johnston, M. A., & Steiner, M. S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70055-x · Cited by 391
Diagnostic accuracy of body mass index to identify obesity in older adults: NHANES 1999–2004
Batsis, J. A., Mackenzie, T. A., Bartels, S. J., Sahakyan, K. R., Somers, V. K., & Lopez-Jimenez, F. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.243 · Cited by 275
Osteosarcopenic obesity: the role of bone, muscle, and fat on health
Ormsbee, M. J., Prado, C. M., Ilich, J. Z., Purcell, S., Siervo, M., Folsom, A., & Panton, L. (2014) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-014-0146-x · Cited by 257 · cited 1×
“There is emerging interest in the co-occurrence of low muscle and excess adiposity, known as sarcopenic obesity,(49) and additionally osteoporosis known as osteo-sarcopenic obesity.(50) Many studies to date have not accounted for the”
BackgroundGarcia, J. M., Boccia, R. V., Graham, C. D., Yan, Y., Duus, E. M., Allen, S., & Friend, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71154-4 · Cited by 218
The obesity paradox in cancer-moving beyond BMI
Strulov Shachar, S., & Williams, G. R. (2017) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0439 · Cited by 198
Goodwin, P. J., Segal, R. J., Vallis, M., Ligibel, J. A., Pond, G. R., Robidoux, A., Blackburn, G. L., Findlay, B., Gralow, J. R., Mukherjee, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1517 · Cited by 197
Total body skeletal muscle mass: estimation by creatine (methyl-d3) dilution in humans
Clark, R. V., Walker, A. C., O'Connor-Semmes, R. L., Leonard, M. S., Miller, R. R., Stimpson, S. A., Turner, S. M., Ravussin, E., Cefalu, W. T., Hellerstein, M. K., et al. (2014) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00045.2014 · Cited by 176
Clinical implications of sarcopenic obesity in cancer
Carneiro, I. P., Mazurak, V. C., & Prado, C. M. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0546-5 · Cited by 162
Sjøblom, B., Grønberg, B. H., Wentzel-Larsen, T., Baracos, V. E., Hjermstad, M. J., Aass, N., Bremnes, R. M., Fløtten, Ø., Bye, A., & Jordhøy, M. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.03.010 · Cited by 143
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial
Golan, T., Geva, R., Richards, D., Madhusudan, S., Lin, B. K., Wang, H. T., Walgren, R. A., & Stemmer, S. M. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12331 · Cited by 109
Murray, T. É., Williams, D., & Lee, M. J. (2017) · Abdominal Radiology · doi:10.1007/s00261-017-1124-5 · Cited by 69
Nishie, K., Yamamoto, S., Nagata, C., Koizumi, T., & Hanaoka, M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.023 · Cited by 52
Cited by
Bossi, P., Delrio, P., Mascheroni, A., & Zanetti, M. (2021) · Nutrients · doi:10.3390/nu13061980 · Cited by 465
Metadata
- Authors
- Brown, J. C., Cespedes Feliciano, E. M., & Caan, B. J.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2018-12
- Volume
- 9
- Issue
- 7
- Pages
- 1200-1208
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W2908632748
- Cited by
- 174
- References
- 22
- FWCI
- 11.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.